Tsubota Laboratory Incorporated

Business Details

The company develops a pipeline of pharmaceuticals and medical devices centered on violet light technology, targeting myopia, dry eye, presbyopia, and brain diseases, with a BtoB business model that generates revenue through upfront licensing fees, milestones, and royalties from out-licensing to partner companies. Key partners include Rohto Pharmaceutical, Maruho, JINS Holdings, and Laboratoires Théa. Revenue depends on the timing of contract execution and development progress, resulting in a structural characteristic of significant year-to-year performance volatility.

Recent Overview

A sharp fall into loss due to the reversal effect of a large upfront licensing fee recorded in the prior period, combined with continued R&D investment; a material event regarding the going concern assumption has arisen

For FY2026 (ending March 2026), revenue was ¥200 million (down 85.3% year on year), and operating loss significantly worsened to ¥787 million. The main cause was the reversal effect from the large upfront licensing fee recorded in the prior fiscal year. Milestone revenue associated with the initiation of Maruho's Phase IIa trial for TLM-001 constituted the main component of revenue for the current period. Selling, general and administrative expenses were ¥919 million, only slightly lower than the prior period, as R&D investment continued. Although there is a statement that an event exists giving rise to material doubt about the going concern assumption, the company holds a cash balance of ¥969 million at period end and, expecting to return to operating profitability in the following fiscal year, has determined that no material uncertainty exists. The forecast for FY2027 (ending March 2027) projects revenue of ¥1,100 million to ¥1,500 million and operating income of ¥5 million to ¥50 million, anticipating a return to profitability.

Key Products

Growth Drivers

• Phased recognition of milestone revenue as Phase II trials progress for TLM-001 (Maruho) and TLM-003 (Rohto Pharmaceutical/Théa)
• Acquisition of milestone revenue and post-launch royalty income for TLG-001 following completion of the pivotal clinical trial and subsequent approval application and approval
• Recognition of upfront contract fee revenue from new out-licensing agreements with domestic and overseas partner companies (from the following fiscal year onward)
• Creation of future out-licensing opportunities through progress in specified clinical studies for new pipeline candidates such as TLM-017, TLG-020, and TLG-021
• Generation of proprietary business revenue and diversification of revenue sources through exclusive domestic distribution of aeonia
• Strengthening of intellectual property and pipeline expansion under the planned ¥400 million R&D investment for the next fiscal year

Risks

• Large single-year performance swings due to variability in the timing of licensing contract execution (current period revenue down 85.3% year on year)
• Risk of failure to conclude new out-licensing agreements and risk of ongoing negotiations being deferred to subsequent periods
• Risk of unmet milestones due to delays or failures in clinical trials conducted by partner companies
• Risk of valuation losses on work in process (¥185 million) due to declining profitability, and risk of additional provisions for contract losses
• Risk of cash consumption due to continued high levels of R&D expenses and SG&A expenses (¥919 million in the current period) (period-end cash balance of ¥969 million)
• Existence of an event giving rise to material doubt about the going concern assumption (although it has been determined that no material uncertainty exists, there is a risk of financial deterioration if profitability is not achieved in the following fiscal year)
• Risk of early termination, at the partner's discretion, of existing licensing agreements and joint research agreements before their contract term expires
• Risk of revenue concentration in specific pipeline candidates and specific partners